16-85918417-C-T
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_002163.4(IRF8):c.602C>T(p.Ala201Val) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00365 in 1,595,148 control chromosomes in the GnomAD database, including 14 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/22 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_002163.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IRF8 | NM_002163.4 | c.602C>T | p.Ala201Val | missense_variant, splice_region_variant | 7/9 | ENST00000268638.10 | NP_002154.1 | |
MIR6774 | NR_106832.1 | downstream_gene_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IRF8 | ENST00000268638.10 | c.602C>T | p.Ala201Val | missense_variant, splice_region_variant | 7/9 | 1 | NM_002163.4 | ENSP00000268638 | P1 | |
MIR6774 | ENST00000614651.1 | downstream_gene_variant |
Frequencies
GnomAD3 genomes AF: 0.00299 AC: 455AN: 152242Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00276 AC: 644AN: 233516Hom.: 2 AF XY: 0.00273 AC XY: 349AN XY: 127762
GnomAD4 exome AF: 0.00372 AC: 5361AN: 1442788Hom.: 14 Cov.: 31 AF XY: 0.00363 AC XY: 2606AN XY: 717876
GnomAD4 genome AF: 0.00299 AC: 455AN: 152360Hom.: 0 Cov.: 33 AF XY: 0.00286 AC XY: 213AN XY: 74500
ClinVar
Submissions by phenotype
Immunodeficiency 32B Pathogenic:1Benign:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 08, 2018 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | May 04, 2023 | This sequence change in IRF8 is predicted to replace alanine with valine at codon 201, p.(Ala201Val). There is a moderate (60-100) physicochemical difference between alanine and valine. The highest population minor allele frequency is in the Latino/Admixed American population with allele frequency of 0.33% (rs144424711, 131/35004 alleles, 1 homozygotes in gnomAD v2.1). Computational evidence is uninformative for the missense substitution (REVEL = 0.306). This variant has been reported in an individual with NK cell deficiency (PMID: 27893462). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.2.1, this variant is classified as LIKELY BENIGN. Following criteria are met: BS1, BP4, PP4 - |
Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency;C4016741:Immunodeficiency 32B Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 05, 2019 | Variant summary: IRF8 c.602C>T (p.Ala201Val) results in a non-conservative amino acid change located in the IRF association domain (Mace 2017) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0026 in 264914 control chromosomes in the gnomAD database, including 2 homozygotes. c.602C>T has been reported in the literature in a compound heterozygous individual (together with c.671C>T (p.Pro224Leu)) affected with Immunodeficiency 32B (Mace 2017). This genotype was not confirmed in the affected sister and other family members who carried either variant in heterozygosity were unaffected; although the observed phenotypes in this family could be consistent with an autosomal recessive inheritance mode, the available data are not sufficient to confirm the role of the variant of interest in association with the disease. The variant was also reported in heterozygous state in two unrelated individuals with pulmonary nontuberculous mycobacterial disease (PNTM) (Mace 2017, Szymanski 2015). These reports therefore do not provide unequivocal conclusion about the association of the variant with Immunodeficiency 32B. One of these studies also reported experimental evidence and demonstrated decreased NK cell number and function, with interrupted NK cell maturation in the compound heterozygous patient, but normal NK cell number and cytotoxic function in the heterozygous carriers (Mace 2017). These data, however, do not allow convincing conclusion about the variant effect. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2024 | IRF8: BS2 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at